Effects of paclitaxel and doxorubicin in histocultures of hepatocelular carcinomas

Journal of Biomedical Science

Volumn 14, Issue 2, 2007, Pages 233-244

  Chuu, Jiunn Jye ^a   Liu, Jacqueline Ming ^a   Tsou, Mei Hua ^b   Huang, Chen Lung ^a   Chen, Ching Ping ^a   Wang, Hsin Sheng ^a   Chen, Chiung Tong ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b Sun Yat Sen Cancer Center   (Taiwan)

Author keywords

Adriamycin; Cancer; Cell death; HCC; Liver; Organ culture; Pharmacodynamics; Taxol; Tumor

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CELL CULTURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE SECTION; TUMOR CELL;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PACLITAXEL; TIME FACTORS;

EID: 34247260411     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9141-3     Document Type: Article

References (50)

1. Montalto G., Cervello M., Giannitrapani L., Dantona F., Terranova A. and Castagnetta L.A, Epidemiology, risk factors, natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 963: 13-20, 2002.
2. El-Serag H.B., Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 35(5 Suppl 2) S72-78, 2002.
3. Llovet J.M., Burroughs A. and Bruix J., Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
4. Bosch F.X., Ribes J, Diaz M and Cleries R, Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1) S5-S16, 2004.
5. Lee Y.T., Primary carcinoma of the liver: diagnosis, prognosis, and management. J. Surg. Oncol. 22: 17-25, 1983.
6. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C. and Thun M.J., Cancer statistics, 2006. CA. Cancer J. Clin. 56: 106-130, 2006.
7. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y. and Chen D.S., Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336: 1855-1859, 1997.
8. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., Tao Q.M., Shue K., Keene O.N., Dixon J.S., Gray D.F. and Sabbat J., Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351: 1521-1531, 2004.
9. Lee C.L., Ko Y.C. and Choong C.S., Survival rate for liver cancer in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 63: 16-20, 2000.
10. Mor E., Kaspa R.T., Sheiner P. and Schwartz M., Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann. Intern. Med. 129: 643-653, 1998.
11. Nagorney D.M., van Heerden J.A., Ilstrup D.M. and Adson M.A., Primary hepatic malignancy: surgical management and determinants of survival. Surgery 106: 740-749, 1989.
12. Tsuzuki T., Sugioka A., Ueda M., Iida S., Kanai T., Yoshii H. and Nakayasu K., Hepatic resection for hepatocellular carcinoma. Surgery 107: 511-520, 1990.
13. Whang-Peng J. and Chao Y., Clinical trials of HCC in Taiwan. Hepatogastroenterology 45: 1937-1943,, 1998.
14. Furukawa T., Kubota T. and Hoffman RM, Clinical applications of the histoculture drug response assay. Clin. Cancer Res. 1: 305-311, 1995.
15. Robbins K.T., Connors K.M., Storniolo AM., Hanchett C and Hoffman R.M., Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch. Otolaryngol. Head Neck Surg. 120: 288-292, 1994.
16. Tanino H., Oura S., Hoffman R.M., Kubota T., Furukawa T., Arimoto J., Yoshimasu T., Hirai I., Bessho T., Suzuma T., Sakurai T. and Naito Y., Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res. 21: 4083-4086, 2001.
17. Chen C.T., Gan Y., Au J.L. and Wientjes M.G., Androgen-dependent and - independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res. 58: 2777-2783,, 1998.
18. Gan Y., Wientjes M.G., Badalament R.A. and Au J.L., Pharmacodynamics of doxorubicin in human bladder tumors. Clin. Cancer Res. 2: 1275-1283, 1996.
19. Tangkijvanich P., Anukulkarnkusol N., Suwangool P., Lertmaharit S., Hanvivatvong O., Kullavanijaya P. and Poovorawan Y., Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J. Clin. Gastroenterol. 31: 302-308, 2000.
20. Soresi M., Magliarisi C., Campagna P., Leto G., Bonfissuto G., Riili A., Carroccio A, Sesti R, Tripi S and Montalto G, Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 23: 1747-1753, 2003.
21. Ohie S., Udagawa Y., Kozu A., Komuro Y., Aoki D., Nozawa S., Moossa A.R. and Hoffman R.M., Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res. 20: 2049-2054, 2000.
22. Hoffman R.M., The clinical benefit of the histoculture drug response assay. Jpn. J. Cancer Chemotherapy 27(Suppl 2) 321-322, 2000.
23. Hoffman R.M., Three-dimensional histoculture: origins and applications in cancer research. Cancer Cell 3: 86-92, 1991.
24. Boess F., Kamber M., Romer S., Gasser R., Muller D., Albertini S. and Suter L., Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73: 386-402, 2003.
25. Jaeschke H., Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity? Hepatology 38: 1053-1055, 2003.
26. Ariyoshi Y., Shimahara M. and Tanigawa N., Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol. 39: 701-707, 2003.
27. Hirano Y., Kageyama S., Ushiyama T., Suzuki K. and Fujita K., Clinical usefulness of chemotherapy based on an in vitro chemosensitivity test in urothelial cancer patients. Anticancer Res. 21: 4061-4066, 2001.
28. Speth P.A., Linssen P.C., Holdrinet R.S. and Haanen C., Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin. Pharmacol. Ther. 41: 661-665, 1987.
29. Bugat R., Robert J., Herrera A., Pinel M.C., Huet S., Chevreau C., Boussin G., Roquain J. and Carton M., Clinical pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. Eur. J. Cancer Clin. Oncol. 25: 505-511, 1989.
30. Adams D.J., In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a novel DNA intercalator. Cancer Res. 49: 6615-6620, 1989.
31. Olweny C.L., Toya T., Katongole-Mbidde E., Mugerwa J., Kyalwazi S.K. and Cohen H., Treatment of hepatocellular carcinoma with adriamycin. Cancer 36: 1250-1257, 1975.
32. Doci R., Bignami P., Bozzetti F., Bonfanti G., Audisio R., Colombo M. and Gennari L., Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 61: 1983-1987, 1988.
33. Barone M., Ettorre G.C., Ladisa R., Schiavariello M., Santoro C., Francioso G., Vinciguerra V. and Francavilla A., Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 50: 183-187, 2003.
34. Raoul J.L., Heresbach D., Bretagne J.F., Bentue Ferrer D., Duvauferrier R., Bourguet P., Messner M. and Gosselin M., Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70: 585-590, 1992.
35. Lai C.L., Wu P.C., Chan G.C., Lok A.S. and Lin H.J., Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62: 479-483, 1988.
36. Cheng J.C., Chuang V.P., Cheng S.H., Huang A.T., Lin Y.M., Cheng T.I., Yang P.S., You D.L., Jian J.J., Tsai S.Y., Sung J.L. and Horng C.F., Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 47: 435-442, 2000.
37. Wilson W.H., Berg S.L., Bryant G., Wittes R.E., Bates S., Fojo A., Steinberg S.M., Goldspiel B.R., Herdt J., O'Shaughnessy J., Balis F.M. and Chabner B.A., Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol. 12: 1621-1629, 1994.
38. Gligorov J. and Lotz J.P., Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl 2) 3-8, 2004.
39. Strumberg D., Erhard J., Harstrick A., Klaassen U., Muller C., Eberhardt W., Wilke H. and Seeber S., Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur. J. Cancer 34: 1290-1292, 1998.
40. Panday V.R.N., ten Bokkel Huinink W.W., Vermorken J.B., Rosing H., Koopman F.J., Swart M., Schellens J.H. and Beijnen J.H., Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. Pharmacol. Res. 40: 67-74, 2004.
41. Seidman A.D., Hochhauser D., Gollub M., Edelman B., Yao T.J., Hudis C.A., Francis P., Fennelly D., Gilewski T.A., Moynahan M.E., Currie V., Baselga J., Tong W., O'Donaghue M., Salvaggio R., Auguste L., Spriggs D. and Norton L., Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol. 14: 1877-1884, 1996.
42. Minemura M., Tanimura H. and Tabor E., Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int. J. Oncol. 15: 559-563, 1999.
43. Nies A.T., Konig J., Pfannschmidt M., Klar E., Hofmann W.J. and Keppler D., Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 94: 492-499, 2001.
44. Chao Y., Chan W.K., Birkhofer M.J., Hu O.Y, Wang S.S., Huang Y.S., Liu M, Whang-Peng J., Chi K.H., Lui W.Y. and Lee S.D., Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br. J. Cancer 78: 34-39, 1998.
45. Fuchs J., Habild G., Leuschner I., Schweinitz D.V., Haindl J. and Knon E., Paclitaxel: an effective antineoplastic agent in the treatment of xenotransplanted hepatoblastoma. Med. Pediatr. Oncol. 32: 209-215, 1999.
46. Chang A.Y., Boros L., Garrow G. and Asbury R., Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin. Oncol. 22(3 Suppl 6) 124-127, 1995.
47. Younes A., Ayoub J.P., Hagemeister F.B., McLaughlin P., Sarris A., Rodriguez M.A., Swan F. Jr., Romaguera J.E., Martin J. and Cabanillas F., No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J. Clin. Oncol. 14: 543-548, 1996.
48. Markman M., Rose P.G., Jones E., Horowitz I.R., Kennedy A., Webster K., Belinson J., Fusco N., Fluellen L., Kulp B., Peterson G. and McGuire W.P., Ninety-six hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J. Clin. Oncol. 16: 1849-1851, 1998.
49. Lopez R.R. Jr., Pan S.H., Lois J.F., McMonigle M.E., Hoffman A.L., Sher L.S., Lugo D. and Makowka L., Transarterial chemoembolization is a safe treatment for unresectable hepatic malignancies. Ann. Surg. 63: 923-926, 1997.
50. Yoon C.J., Chung J.W., Park J.H., Yoon Y.H., Lee J.W., Jeong S.Y. and Chung H., Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229: 126-131, 2003.